FDA Inspection 1237445 — Slate Run Pharmaceuticals
The FDA completed an inspection of Slate Run Pharmaceuticals on Dec 5, 2024 in Columbus, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Dec 5, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Columbus, OH (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)